EMEA-002490-PIP01-18 - paediatric investigation plan

Mavorixafor
PIPHuman

Key facts

Active Substance
Mavorixafor
Therapeutic area
Congenital, familial and genetic disorders
Decision number
P/0185/2024
PIP number
EMEA-002490-PIP01-18
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral liquid dosage form
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome
Route(s) of administration
Oral use
Contact for public enquiries

E-mail: clinicaltrialinfo@x4pharma.com 
Tel.:  +1 18575295779

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date

Decision

Share this page